We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Bisphosphonates Improve QOL in Bone Lesion Patients

Sep 1, 1997
Volume: 
6
Issue: 
9
  • Multiple Myeloma

BETHESDA, Md—Less than two years ago, the FDA approved Aredia (pamidronate disodium for injection) as the first agent for the treatment of osteo-lytic bone lesions in multiple myeloma patients, to be used in conjunction with standard antimyeloma chemotherapy.

James Berenson, MD, professor of medicine, UCLA School of Medicine, was principal investigator of clinical trials of the bisphosphonate, sponsored by Ciba Pharmaceuticals and Chiron Corporation, that preceded FDA approval.

“For the first time, with Aredia, physicians are able to provide multiple myeloma patients with a drug that reduces the incidence of pathologic fractures, relieves bone pain and substantially preserves the quality of their lives,” Dr. Berenson said at a symposium on the skeletal complications of malignancy, sponsored by the Paget Foundation and the National Cancer Institute.

Bisphosphonates: A Brief History

Malignant bone damage is caused by the activity of bone-resorbing cells (osteoclasts) stimulated by tumor cell products. Bisphosphonates are stable chemical analogues of pyrophosphate, a naturally occurring regulator of bone mineral accretion and dissolution. They function as powerful inhibitors of osteoclast function.

The first clinical use of bis-phosphonates came in the 1960s when they were employed as agents for bone scanning, based on their ability to adsorb to bone mineral. At the same time, they were shown to be effective in clinical disorders associated with increased bone resorption, at first in Paget’s disease of bone and later in hypercalcemia of malignancy, myeloma, and bone metastases.

Continued testing has fueled considerable optimism regarding the effectiveness of the bis-phosphonates as adjunctive treatment for skeletal complications associated not only with multiple myeloma (see article above) but also with breast cancer, prostate cancer, and other cancers.

Pamidronate, a relatively potent aminobisphosphonate administered intravenously, has proved more effective than weaker, first-generation bisphos-phonates taken orally. Oral clodronate does reduce the development of new osteolytic lesions, Dr. Berenson said, but it does not significantly affect bone pain or the development of pathologic bone fractures.

In the pivotal trial of pamidronate, multiple myeloma patients with at least one lytic lesion were randomized to receive a monthly four-hour intravenous infusion of either pamidronate, 90 mg, or placebo for 21 cycles, in addition to chemotherapy.

Significant Decrease in Pain

Among 392 patients entered into the study, 377 were evaluated for skeletal events (pathological fracture, irradiation or surgery to bone, and spinal cord compression).

Patients who received pamidronate had significant decreases in bone pain, required less analgesia, and suffered fewer skeletal events than patients on placebo. Overall survival, however, was not significantly affected.

Dr. Berenson said that there is much to be learned about how these drugs work. Neverthess, he added, the bisphospho-nates “have proved safe and relatively without side effects for most patients for whom they significantly improve quality of life.”

In recent years researchers have succeeded in increasing the potency of bisphosphonates as inhibitors of bone resorption by as much as 100- to 10,000- fold, said Dr. Graham Russell, of the Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, England.

These compounds, which include risedronate, ibandronate, and zoledro-nate, are able to suppress bone resorption in experimental animals at doses of less than 1 µg/day.

It is anticipated, Dr. Russell said, that several of these new and more potent bisphosphonates will be approved for use in the near future.

Related Articles

  • Excess Mortality Risk Shows Myeloma Is Still ‘Incurable’
  • High BMI in Early Adulthood Increased Myeloma Risk
  • Ixazomib Triplet Combo Effective in R/R Myeloma
  • Pomalidomide/Dexamethasone Effective in R/R Myeloma With Renal Insufficiency
  • Denosumab Approved for Skeletal-Related Events in Myeloma

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.